Expand All | Contract All

Menu Bottom Graphic



PDGF is a substance that is involved in the activation of the cells of the defence system and it also contributes to the wound healing process. Simultaneously it has the potential to be pathogenic and can prevent the destruction of tumour cells thereby enabling further development of the condition to take place. High quantities are primarily associated with tumour development and, also, an imminent risk of the development of arteriosclerosis. Low quantities are an indication that there is a reduced number of normal platelets available to create haemostasis.


PDGF is released from platelets during blood clot formation and is the principal mitogen in serum. PDGF increases extracellular matrix Synthesis and activates neutrophils, monocytes and fibroblasts, e.g. the cells of the defence system. It also, together with other factors, accelerates wound healing. However it may be pathogenic in neoplasia when it binds to one of its receptors, namely the platelet derived growth factor receptor beta, located on any tumour cells to prevent their destruction. PDGF is also pathogenic in arteriosclerosis. This assay is designed to evaluate the presence of one of the main growth factors which contributes to the development of a cancer and cardiovascular disease.

High PDGF quantities are associated with an imminent risk of arteriosclerosis and, if there is a cancer, with the presence of transformed cells which are resistant to destruction. Low PDGF quantities indicate a risk of a reduced number of normally functioning platelets which are necessary for normal haemostasis.


This assay will provide extremely valuable and accurate information relating to all forms of cancer.
© Copyright Neuro-Lab 2011
All Rights Reserved

Valid XHTML 1.0 Transitional Myo International Valid CSS!